Literature DB >> 17503155

Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma.

Kazuaki Shimada1, Yoshihiro Sakamoto, Minoru Esaki, Tomoo Kosuge, Chigusa Morizane, Masafumi Ikeda, Hideki Ueno, Takuji Okusaka, Yasuaki Arai, Kenichi Takayasu.   

Abstract

BACKGROUND: Survival analysis in patients with initial recurrence after curative hepatectomy for hepatocellular carcinoma (HCC) has not been well evaluated. In addition, selections of the most effective treatments for patients with recurrent HCC still remain controversial.
METHODS: Three hundred and nineteen patients who underwent potentially curative hepatectomies were followed for initial recurrence, and factors predictive of recurrence were determined. The factors affecting survival including pattern of recurrence and treatment modalities from the time of initial recurrence in 211 patients were retrospectively analyzed.
RESULTS: The overall 5-year disease-free survival rate of 319 patients was 31.1%. The 5-year survival rate of 211 patients from the time of initial recurrence was 31.9%. In a multivariate analysis, a low indocyanine green retention rate, lack of liver cirrhosis, a long interval before recurrence, the absence of portal vein invasion, and intrahepatic recurrence (<or=3 nodules) were shown to be significantly favorable prognostic factors after the initial recurrence. The 5-year survival rate of patients with intrahepatic recurrence (<or=3 nodules) was 42.3%, and no survival differences were observed among different treatment modalities.
CONCLUSION: When the initial recurrence occurred after a longer interval, and/or with three or fewer intrahepatic recurrent nodules, a favorable prognosis could be expected in those patients with better liver function and no portal vein invasion at the time of the primary hepatectomy. It is important to conduct a randomized controlled trial to clarify a method for selecting optimal treatment in patients with a smaller number of initial intrahepatic recurrences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503155     DOI: 10.1245/s10434-007-9415-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Yusuke Yamamoto; Hisashi Ikoma; Ryo Morimura; Hirotaka Konishi; Yasutoshi Murayama; Shuhei Komatsu; Atsushi Shiozaki; Yoshiaki Kuriu; Takeshi Kubota; Masayoshi Nakanishi; Daisuke Ichikawa; Hitoshi Fujiwara; Kazuma Okamoto; Chouhei Sakakura; Toshiya Ochiai; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection.

Authors:  Tsuyoshi Notake; Akira Kobayashi; Hiroji Shinkawa; Takuya Kawahara; Akira Shimizu; Takahide Yokoyama; Kiyoshi Hasegawa; Norihiro Kokudo; Yutaka Matsuyama; Masatoshi Makuuchi; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2017-03-16       Impact factor: 3.402

3.  Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma.

Authors:  Tomoki Kobayashi; Hiroshi Aikata; Masahiro Hatooka; Kei Morio; Reona Morio; Hiromi Kan; Hatsue Fujino; Takayuki Fukuhara; Keiichi Masaki; Atsushi Ohno; Noriaki Naeshiro; Takashi Nakahara; Yohji Honda; Eisuke Murakami; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hideyuki Hyogo; Shoichi Takahashi; Kazuaki Chayama
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

Review 4.  Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection.

Authors:  Kang Mo Kim
Journal:  Hepat Oncol       Date:  2015-01-12

5.  Repeat treatment for recurrent hepatocellular carcinoma: is it validated?

Authors:  Yoji Kishi; Akio Saiura; Junji Yamamoto; Rintaro Koga; Makoto Seki; Ryo Morimura; Ryuji Yoshioka; Norihiro Kokudo; Toshiharu Yamaguchi
Journal:  Langenbecks Arch Surg       Date:  2011-08-17       Impact factor: 3.445

Review 6.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

Review 7.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

8.  The role of liver transplantation or resection for patients with early hepatocellular carcinoma.

Authors:  Kuan-Chun Hsueh; Ting-Ying Lee; Chew-Teng Kor; Tsung-Ming Chen; Tzu-Ming Chang; Shun-Fa Yang; Chung-Bao Hsieh
Journal:  Tumour Biol       Date:  2015-10-22

9.  18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma.

Authors:  Hironori Ochi; Masashi Hirooka; Atsushi Hiraoka; Yohei Koizumi; Masanori Abe; Ichiro Sogabe; Yoshihiro Ishimaru; Keizou Furuya; Masao Miyagawa; Hideki Kawasaki; Kojiro Michitaka; Yasutsugu Takada; Teruhito Mochizuki; Yoichi Hiasa
Journal:  Mol Clin Oncol       Date:  2014-06-25

10.  Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma.

Authors:  Weiqi Rong; Yang Zhang; Lei Yang; Lin Feng; Baojun Wei; Fan Wu; Liming Wang; Yanning Gao; Shujun Cheng; Jianxiong Wu; Ting Xiao
Journal:  Front Med       Date:  2018-05-16       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.